Exercise of Share Options & Total Voting Rights

Venture Life Group PLC

23 May 2024

 

23 May 2024

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Exercise of Share Options & Total Voting Rights

Venture Life Group PLC (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that it has issued 149,516 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options, subject to admission to trading on AIM.

Application has been made to the London Stock Exchange for the 149,516 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 29 May 2024.

Following Admission, the total number of Ordinary Shares in issue will be 126,647,713 and the total number of voting rights will therefore be 126,647,713. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Venture Life Group PLC                                                                                                    [phone]

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and Broker)                                            [phone] 

Stephen Keys/Camilla Hume (Corporate Finance)

Michael Johnson (Sales) 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, and Sweden, the Group's product portfolio includes some key products such as the Balance Active range in the area of women's intimate healthcare, the Earol® product line in ENT care, the Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the UltraDEX and Dentyl oral care product ranges, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

 

END